221 related articles for article (PubMed ID: 1768837)
1. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
Yue TL; Rabinovici R; Farhat M; Feuerstein G
J Lipid Mediat; 1991; 3(1):13-26. PubMed ID: 1768837
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
5. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
6. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
[TBL] [Abstract][Full Text] [Related]
7. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
Rabinovici R; Yue TL; Farhat M; Smith EF; Esser KM; Slivjak M; Feuerstein G
J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
9. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
Adamus WS; Heuer H; Meade CJ
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity.
Castro-Faria-Neto HC; Martins MA; Silva PM; Bozza PT; Cruz HN; de Queiroz-Paulo M; Kaplan MA; Cordeiro RS
J Lipid Mediat; 1993 May; 7(1):1-9. PubMed ID: 8358020
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
12. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo.
Yue TL; Rabinovici R; Farhat M; Feuerstein G
Prostaglandins; 1990 May; 39(5):469-80. PubMed ID: 2353116
[TBL] [Abstract][Full Text] [Related]
15. [Effects of ketotifen on rabbit platelet aggregation and platelet activating factor formation from rat neutrophils].
Wang XD; Bian RL
Zhongguo Yao Li Xue Bao; 1990 Nov; 11(6):524-7. PubMed ID: 2130617
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
18. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
20. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]